Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tie-2 Antibody (tek9) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: Novus Biologicals NBP1186140.02MG
Description
Tie-2 Monoclonal specifically detects Tie-2 in Human samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Sandwich ELISA, CyTOF-ready.Specifications
| Tie-2 | |
| Monoclonal | |
| LYOPH | |
| Western Blot 2 - 5 ug/ml, Flow Cytometry 2 - 5 ug/ml, ELISA 1 - 2 ug/ml, Immunohistochemistry, Immunocytochemistry/Immunofluorescence 1 - 5 ug/ml, Sandwich ELISA, CyTOF-ready | |
| angiopoietin-1 receptor, CD202B, CD202b antigen, EC 2.7.10, EC 2.7.10.1, hTIE2, p140 TEK, soluble TIE2 variant 1, soluble TIE2 variant 2, TEK tyrosine kinase, endothelial, TIE-2, TIE2CD202b, Tunica interna endothelial cell kinase, Tyrosine-protein kinase receptor TEK, Tyrosine-protein kinase receptor TIE-2, venous malformations, multiple cutaneous and mucosal, VMCM, VMCM1 | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Primary | |
| The monoclonal antibody will detect native human TIE-2/tek in ELISA experiments and on the surface of different human cell types. | |
| Human | |
| Purified |
| Flow Cytometry, Western Blot, Immunofluorescence, ELISA, Immunohistochemistry, Immunocytochemistry | |
| tek9 | |
| Unconjugated | |
| PBS with No Preservative | |
| TEK | |
| recombinant human Jagged-1 | |
| 0.02 mg | |
| Angiogenesis, Cancer, Protein Kinase | |
| 7010 | |
| Reconstitute the antibody with 500 ul sterile PBS and the final concentration is 200 ug/ml. | |
| Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
| IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction